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Abstract
Two genetically related Klebsiella pneumoniae strains carrying
OXA-type carbapenemases were isolated from a single patient 1
month apart. Kpn163 harboured OXA-163 and Kpn247 a new
variant named OXA-247 that showed susceptibility to carbapen-
ems and expanded-spectrum cephalosporins similar to OXA-48.
Our epidemiological, biochemical and molecular results suggest
the intrapatient emergence of blaOXA-247 from blaOXA-163.
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Carbapenem-hydrolyzing class D b-lactamases (CHDLs)
hydrolyze carbapenems at low levels but do not have activity
against extended-spectrum cephalosporins (ESCs) and aztreo-
nam, which hinder their detection at the clinical microbiology
laboratory [1,2]. Nowadays, CHDLs such as OXA-48-type
enzymes are circulating among Mediterranean countries and
are progressively disseminating to other geographical areas [3].
OXA-163 is an OXA-48-related enzyme with a weaker
carpabenem activity but a higher hydrolytic activity against
ESCs that has recently been reported in Argentina and later in
Egypt (22nd European Congress of Clinical Microbiology and
Infectious Diseases, Abstr. P1699) [4,5]. In Argentina, OXA-
163 was ﬁrst described in Klebsiella pneumoniae and Enterob-
acter cloacae [4]. Later, we described the broad spread of
multiple clones of OXA-163-producing K. pneumoniae and
E. cloacae from nine hospitals (22nd European Congress of
Clinical Microbiology and Infectious Diseases, Abstr. P1699).
Here, we report the characterization of two K. pneumoniae
clinical strains, isolated 1 month apart from the same patient,
that belonged to the same clonal type but harboured different
CHDLs: blaOXA-163 and a new variant of this enzyme, blaOXA-247.
A 15-year-old female diagnosed with acute lymphoid leuke-
mia at the age of 3, was hospitalized in August 2010 and was
subjected to a decolonization treatment with penicillin and
colistin as part of a bone marrow transplant (BMT) protocol.
Four days after BMT the patient developed febrile syndrome
(FS) and sinusitis, and received empirical treatment with
piperacillin-tazobactam, amikacin and vancomycin. Six days
after, a positive blood culture was obtained with an expanded-
spectrum-b-lactamase (ESBL)-producing E. cloacae resistant to
amikacin; therefore the treatment was replaced by merope-
nem, colistin and amphotericin B. Twelve days later a new
blood culture yielded a K. pneumoniae (Kpn163) suspicious for
carbapenemase production. Susceptibility testing of Kpn163
(disk diffusion method and microdilution, Clinical and Labora-
tory Standards Institute-CLSI 2012 [6]), showed resistance to
all b-lactams (including carbapenems), fosfomycin i.v. (European
Committee on Antimicrobial Susceptibility Testing-EUCAST
criteria) (http://www.eucast.org/clinical_breakpoints/), colistin,
trimethoprim/sulphamethoxazole, chloramphenicol, tetracy-
clines and rifampin. Kpn163 remained susceptible to aminogly-
cosides, tigecycline (EUCAST) and quinolones. The treatment
was replaced by gentamicin and ciproﬂoxacin with clinical
success. A month later, a second BMT was performed and FS
developed again. The patient was empirically treated with
colistin and vancomycin but a week later, a second K. pneumo-
niae (Kpn247) was recovered from the paranasal sinuses. The
susceptibility proﬁle of Kpn247 was similar to that of Kpn163
with exceptions: the aminoglycosides and quinolones became
resistant, and unexpectedly, Kpn247 restored the susceptibility
to ESCs and aztreonam (Table 1). The patient died a day after
Kpn247 isolation due to a massive infection with cytomegalo-
virus and graft vs. host disease. Both isolates were referred to
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the National Reference Laboratory (INEI–Malbran) for their
characterization.
blaTEM, blaSHV, blaOXA-163 and aac(6′)-Ib-cr were ampliﬁed by
PCR in both Kpn163 and Kpn247 (Table 1). Locally prevalent
b-lactamase (i.e. blaKPC, blaPER, blaCTX-M and blaGES) were PCR
negative. PstI-digested plasmidic DNA was ligated and ampliﬁed
with outward primers to obtain the complete blaOXA genes.
Kpn163 harboured blaOXA-163 and Kpn247 a new variant with
two amino acid substitutions (Y219S and D220N, DBL num-
bering) assigned blaOXA-247 (GenBank JX893517). The immedi-
ate genetic surroundings of both blaOXA alleles were identical to
that previously described [4] (i.e. bracketed upstream by
the insertion sequence IS4321 and downstream by a truncated
IS4-like element; data not shown).
Both genes were transferred by biparental conjugation to
Escherichia coli J53 (sodium azide-resistant) [7], rendering
TC163 and TC247 from Kpn163 and Kpn247, respectively.
Imipenem MICs of both transconjugants were eight times
higher than that of the acceptor strain but the MICs of
meropenem or ertapenem remained the same (Table 1). A
modiﬁed Hodge test (MHT) to carbapenems [8] was positive
for both transconjugants (Table 1).
Isoelectric focusing (IEF) [9] gave bands at pIs 5.6 (TEM) and
7.6 (SHV) in both strains, and pI 6.7 (OXA-163-Kpn163) and pI
7.0 (OXA-247-Kpn247) (Table 1). The shift of the pI from 6.7
to 7.0 when comparing OXA-163 and OXA-247 agrees with
the substitution of the acidic aspartic acid residue to the
neutral asparagine (D220N).
S1 nuclease digestion [10] showed that Kpn163 carried two
plasmids of 70 Kb and 190 Kb while Kpn247 carried three
plasmids of 70, 170 and 190 Kb in both isolates, the band of 70
Kb hybridized with the blaOXA-163/247 probe. TC163 and
TC247 carried a 70 Kb non-typeable plasmid (PCR-based
replicon typing [11]) that hybridized with the blaOXA-163/247
probe. These results suggest that both enzymes might be
carried in the same plasmid.
Outer membrane protein-encoding genes, ompK35 and
ompK36, were ampliﬁed by PCR [12], sequenced and com-
pared with K. pneumoniae MGH78578 [5]. ompK35 of both
isolates were identical and showed ﬁve synonymous mutations
and a 4-nucleotide insertion (CCAC) after codon 196, giving a
deduced truncated product of 213 amino-acids. Kpn163
harboured a wild-type ompK36 sequence while Kpn247 had a
5-nucleotide deletion at codons 44 and 45 that produced a
premature termination codon with a deduced truncated
product of 43 amino acids.
Pulsed-ﬁeld gel electrophoresis (PFGE) studies revealed that
Kpn163 and Kpn247 were clonally related, with only one band
of difference in the macrorestriction pattern. Multilocus
sequence typing (MLST) was performed according to the
MLST Database (http://www.pasteur.fr/recherche/genopole/
PF8/mlst/) and both isolates belonged to ST37, also reported
in a clinical isolate from Egypt expressing blaOXA-163 [5].
In this case report we found the novel variant blaOXA-247 in
an immunosuppressed patient who received several antibiotic
treatments and who was previously infected with a genetically
related K. pneumoniae harbouring blaOXA-163. Of note, to the
best of our knowledge, the patient had not had any admissions
to other health institutions from Buenos Aires City. In
addition, this was the only report of OXA-type enzymes in
TABLE 1. Antimicrobial drug susceptibility, microbiological activity, isoelectric focusing and PCR of antimicrobial resistance
determinants in the studied isolates, transcojugants and recipient strain
Clinical isolates Transconjugants
Acceptor
K. pneumoniae Kpn163 K. pneumoniae Kpn247 E. coli TC163 E. coli TC247 E. coli J53
MICs in μg/ml
Imipenem 8 16 0.5 0.5 0.06
Meropenem 32 16 0.03 0.03 0.03
Ertapenem >256 >256 0.5 0.5 0.12
Cefotaxime >256 1 128 0.12 0.12
Ceftazidime >256 16 >256 2 0.12
Cefepime >256 8 64 1 0.12
Aztreonam 128 32 64 8 0.12
Modiﬁed Hodge test to carbapenems
MHT result + + + + 
Isoelectric focusing
pI bands 5.6; 6.7; 7.6 5.6; 7; 7.6 5.6; 6.7 5.6; 7 ND
Gene detected PCR results
blaOXA-163 +  +  ND
blaOXA-247  +  + ND
blaTEM-1 + + + + ND
blaSHV-1 + +   ND
aac(6´)Ib-cr + + + + ND
MHT, modiﬁed Hodge test; ND, not determined; pI, isoelectric point; +, positive; , negative.
pI bands of OXA-163 and OXA-247 are indicated in bold.
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the hospital involved. This epidemiological setting in conjunc-
tion with the results of PFGE, plasmid content, genetic
environment and porin analysis are consistent with the
hypothesis of an intrapatient emergence of blaOXA-247 from
the previously established blaOXA-163. The implications of
OXA-247 in the local epidemiology remain to be determined.
Nucleotide Sequence Accession Number
The nucleotide sequence of blaOXA-247 has been assigned
GenBank accession number JX893517, (http://www.ncbi.nlm.
nih.gov/genbank/index.html).
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